Faster Access In England Under NICE-MHRA Scheme Hinges On ‘Optimal’ Drug Status

 
• By Eliza Slawther
  
Companies that want to benefit from faster HTA decisions in England must be ready to submit evidence early (Shutterstock)

More from Health Technology Assessment

More from Europe